Apolipoprotein e polymorphism and expression in type 2 diabetic patients with nephropathy: Clinicopathological correlation

Nephrology Dialysis Transplantation

Volumn 24, Issue 6, 2009, Pages 1889-1895

  Guan, Jing ^a   Zhao, Hai Lu ^a   Baum, Larry ^a   Sui, Yi ^a   He, Lan ^a   Wong, Harriet ^a   Lai, Fernand M M ^a   Tong, Peter C Y ^a,b   Chan, Juliana C N ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Apolipoprotein E; Diabetic nephropathy; Glomerulopathy

Indexed keywords

APOLIPOPROTEIN E; GENOMIC DNA;

AGED; ARTICLE; AUTOPSY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; EXON; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GLOMERULOSCLEROSIS; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY HYPERTROPHY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SPLEEN;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; APOLIPOPROTEINS E; AUTOPSY; BASE SEQUENCE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DNA PRIMERS; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KIDNEY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 67651120056     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn734     Document Type: Article

References (47)

1. Ritz E, Rychlik I, Locatelli F et al. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795-808
2. Critchley JA, Zhao HL, Tomlinson B et al. Management of nephropathy in patients with type 2 diabetes. Chin Med J (Engl) 2002; 115: 129-135
3. Wu AY, Kong NC, de Leon FA et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 2005; 48: 17-26
4. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-360
5. Mazzucco G, Bertani T, Fortunato M et al. Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies. Am J Kidney Dis 2002; 39: 713-720
6. Zhao HL, Lai FM, Tong PC et al. Clinicopathologic characteristics of nodular glomerulosclerosis in Chinese patients with type 2 diabetes. Am J Kidney Dis 2004; 44: 1039-1049
7. So WY, Ma RC, Ozaki R et al. Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients - interaction with ACE insertion/deletion polymorphism. Kidney Int 2006; 69: 1438-1443
8. Bowden DW, Sale M, Howard TD et al. Linkage of genetic markers on human chromosomes 20 and 12 to NIDDM in Caucasian sib pairs with a history of diabetic nephropathy. Diabetes 1997; 46: 882-886
9. Langefeld CD, Beck SR, Bowden DW et al. Heritability of GFR and albuminuria in Caucasians with type 2 diabetes mellitus. Am J Kidney Dis 2004; 43: 796-800
10. Zhao HL, Tong PC, Lai FM et al. Association of glomerulopathy with the 5′ -end polymorphism of the aldose reductase gene and renal insufficiency in type 2 diabetic patients. Diabetes 2004; 53: 2984-2991
11. Liberopoulos E, Siamopoulos K, Elisaf M. Apolipoprotein E and renal disease. AmJKidneyDis 2004; 43: 223-233
12. Ng MC, Baum L, So WY et al. Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3-455T>C polymorphisms on the susceptibility to diabetic nephropathy. Clin Genet 2006; 70: 20-28
13. M Eto, Saito M, Okada M et al. Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis 2002; 40: 243-251
14. Hsieh MC, Lin SR, Yang YC et al. Higher frequency of apolipoprotein E2 allele in type 2 diabetic patients with nephropathy in Taiwan. J Nephrol 2002; 15: 368-373
15. Ha SK, Park HS, Kim KW et al. Association between apolipoprotein E polymorphism and macroalbuminuria in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transplant 1999; 14: 2144-2149
16. Eto M, Horita K, Morikawa A et al. Increased frequency of apolipoprotein epsilon 2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy. Clin Genet 1995; 48: 288-292
17. Levey AS, Bosch JP, Lewis JB et al. Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461-470
18. American Diabetes Association. Diagnosis and classification of diabetes smellitus. Diabetes Care 2004; 27(Suppl 1): S5-S10
19. Nishi S, Ueno M, Hisaki S et al. Ultrastructural characteristics of diabetic nephropathy. Med Electron Microsc 2000; 33: 65-73
20. Shi SR, Cote RJ, Wu L et al. DNA extraction from archival formalin-fixed, paraffin-embedded tissue sections based on the antigen retrieval principle: heating under the influence of pH. J Histochem Cytochem 2002; 50: 1005-1011
21. Khanna M, Park P, Zirvi M et al. Multiplex PCR/LDR for detection of K-ras mutations in primary colon tumors. Oncogene 1999; 18: 27-38
22. Kwon MK, Rhee SY, Chon S et al. Association between apolipoprotein E genetic polymorphism and the development of diabetic nephropathy in type 2 diabetic patients. Diabetes Res Clin Pract 2007; 77(Suppl 1): S228-232
23. Araki S, Koya D, Makiishi T et al. APOE polymorphism and the progression of diabetic nephropathy in Japanese subjects with type 2 diabetes: results of a prospective observational follow-up study. Diabetes Care 2003; 26: 2416-2420
24. Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci 2006; 31: 445-454
25. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteinearginine interchange at a single site. JBiolChem 1982; 257: 2518-2521
26. Mahley RW, Rall SC, Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000; 1: 507-537
27. Saito M, Eto M, Makino I. Triglyceride-rich lipoproteins from apolipoprotein E3/2 subjects with hypertriglyceridemia enhance cholesteryl ester synthesis in human macrophages. Atherosclerosis 1997; 129: 73-77
28. Bonnet F, Cooper ME. Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabetes Metab 2000; 26: 254-264
29. Nishida Y, Oda H, Yorioka N. Effect of lipoproteins on mesangial cell proliferation. Kidney Int Suppl 1999; 71: S51-S53
30. Saraswathi V, Hasty AH. The role of lipolysis in mediating the proinflammatory effects of very low density lipoproteins in mouse peritoneal macrophages. J Lipid Res 2006; 47: 1406-1415
31. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-219
32. Tenger C, Zhou X. Apolipoprotein E modulates immune activation by acting on the antigen-presenting cell. Immunology 2003; 109: 392-397
33. Mahley RW, Huang Y. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol 1999; 10: 207-217
34. Hsu CC, Kao WH, Coresh J et al. Apolipoprotein E and progression of chronic kidney disease. JAMA 2005; 293: 2892-2899
35. Boizel R, Benhamou PY, Corticelli P et al. ApoE polymorphism and albuminuria in diabetes mellitus: a role for LDL in the development of nephropathy in NIDDM? Nephrol Dial Transplant 1998; 13: 72-75
36. Lehtinen S, Rantalaiho V, Wirta O et al. Apolipoprotein E gene polymorphism, hypercholesterolemia and glomerular filtration rate in type 2 diabetic subjects: a 9-year follow-up study. J Biomed Sci 2003; 10: 260-265
37. Chen G, Paka L, Kako Y et al. A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion. JBiolChem 2001; 276: 49142-49147
38. Takemura T, Yoshioka K, Aya N et al. Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int 1993; 43: 918-927
39. Sato H, Suzuki S, Kobayashi H et al. Immunohistological localization of apolipoproteins in the glomeruli in renal disease: specifically apoB and apoE. Clin Nephrol 1991; 36: 127-133
40. Ilveskoski E, Perola M, Lehtimaki T et al. Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: an autopsy study. Circulation 1999; 100: 608-613
41. Baum L, Ng HK, Wong KS et al. Associations of apolipoprotein E exon 4 and lipoprotein lipase S447 X polymorphisms with acute ischemic stroke and myocardial infarction. Clin Chem Lab Med 2006; 44: 274-281
42. Mayeux R, Saunders AM, Shea S et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. NEnglJMed 1998; 338: 506-511
43. Dong LM, Weisgraber KH. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. JBiolChem 1996; 271: 19053-19057
44. Nickenig G, Sachinidis A, Michaelsen F et al. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95: 473-478
45. Bruneval P, Bariety J, Belair MF et al. Mesangial expansion associated with glomerular endothelial cell activation and macrophage recruitment is developing in hyperlipidaemic apoE null mice. Nephrol Dial Transplant 2002; 17: 2099-2107
46. Tamaoka A, Miyatake F, Matsuno S et al. Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer's disease. Neurology 2000; 54: 2319-2321
47. Brocco E, Fioretto P, Mauer M et al. Renal structure and function in non-insulin dependent diabetic patients with microalbuminuria. Kidney Int Suppl 1997; 63: S40-S44